What is AB Biosciences?
Founded in 2007 and headquartered in Massachusetts, AB Biosciences operates at the intersection of advanced protein engineering and therapeutic development. The company has established a robust reputation for its dual-focus approach: the creation of high-precision therapeutic biologics and the production of specialized research protein reagents. By leveraging a sophisticated R&D platform, AB Biosciences targets the modulation of antigenic activities, specifically addressing complex immuno-oncological disorders. This dual-track business model allows the firm to maintain a steady revenue stream through research tools while simultaneously advancing a high-value pipeline of clinical-stage therapeutic candidates.
How much funding has AB Biosciences raised?
AB Biosciences has raised a total of $70K across 1 funding round:
Debt
$70K
Debt (2021): $70K with participation from PPP
Key Investors in AB Biosciences
PPP
Public-Private Partnership
What's next for AB Biosciences?
With the recent infusion of capital, AB Biosciences is well-positioned to accelerate its clinical development programs and scale its manufacturing capabilities. The strategic focus will likely shift toward expanding the reach of its therapeutic biologics, particularly those designed to modulate effector molecules in cancer treatment. As the company transitions through this growth phase, stakeholders will be monitoring the progression of its lead candidates through regulatory milestones. The firm's ability to maintain its competitive edge in protein design will be critical as it seeks to capture a larger share of the rapidly evolving immuno-oncology market, potentially setting the stage for future strategic partnerships or further institutional investment.
See full AB Biosciences company page
